NO20071873L - DNA-PK inhibotorer. - Google Patents

DNA-PK inhibotorer.

Info

Publication number
NO20071873L
NO20071873L NO20071873A NO20071873A NO20071873L NO 20071873 L NO20071873 L NO 20071873L NO 20071873 A NO20071873 A NO 20071873A NO 20071873 A NO20071873 A NO 20071873A NO 20071873 L NO20071873 L NO 20071873L
Authority
NO
Norway
Prior art keywords
optionally substituted
alkyl
hydrogen
aryl
group
Prior art date
Application number
NO20071873A
Other languages
English (en)
Inventor
Roger John Griffin
Ian Robert Hardcastle
Keith Allan Menear
Greame Cameron Murray Smith
Niall Morrison Barr Martin
Marc Geoffrey Hummersone
Laurent Jean Martin Rigoreau
Bernard Thomas Golding
David Richard Newell
Hillary Alan Calvert
Nicola Jane Curtin
Kappusamy Saravann
Original Assignee
Kudos Pharm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kudos Pharm Ltd filed Critical Kudos Pharm Ltd
Publication of NO20071873L publication Critical patent/NO20071873L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

En forbindelse med formel I: og isomerer, salter, solvater, kjemisk beskyttede former og prodrug derav, hvori: R1 og R2 er uavhengig valgt fra hydrogen, en eventuelt substituert C1-7 alkylgruppe,C3-20 heterocyklylgruppe eller C5-10 arylgruppe, eller kan sammen danne, som nitrogenet til hvilket de er bundet, en eventuelt substituert heterosyklisk ring som har 4-8 ringatomer;Q er -NH-C(=O)- eller -O-; Y er en eventuelt substituert C1-5 alkylengruppe; X er valgt fra SR3 eller NR4R5, hvori R3 eller R4 og R5 er uavhengig valgt fra hydrogen, eventuelt substituerte C1-7 alkyl, C5-20 aryl eller C3-20 heterocyklylgrupper, eller R4 og R5 kan sammen danne, sammen med nitrogenatomet til hvilket de er bundet, en eventuelt substituert heterosyklisk ring som har fra 4 til 8 ringatomer; hvis Q er -O-, er X ytterligere valgt fra -C(=O)-NR6R7, hvori R6 og R7er uavhengig valgt fra hydrogen, eventuelt substituert C1-7 alkyl, C5-20 aryl eller C3-20 heterocyklylgrupper eller R6 og R7 kan sammen danne, sammen med nitrogenatomet til hvilket de er bundet, en eventuelt substituert heterosyklisk ring som har fra 4-8 ringatomer; og hvis Q er -NH- C(=O)-, kan -Y-X- i tillegg være valgt fra C1-7 alkyl.
NO20071873A 2004-09-20 2007-04-12 DNA-PK inhibotorer. NO20071873L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US61151504P 2004-09-20 2004-09-20
PCT/GB2005/003621 WO2006032869A1 (en) 2004-09-20 2005-09-20 Dna-pk inhibitors

Publications (1)

Publication Number Publication Date
NO20071873L true NO20071873L (no) 2007-06-15

Family

ID=35610093

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20071873A NO20071873L (no) 2004-09-20 2007-04-12 DNA-PK inhibotorer.

Country Status (16)

Country Link
US (3) US20070238731A1 (no)
EP (1) EP1794151A1 (no)
JP (1) JP2008513428A (no)
KR (1) KR20070059156A (no)
CN (1) CN101061111A (no)
AU (1) AU2005286329A1 (no)
BR (1) BRPI0515498A (no)
CA (1) CA2580229A1 (no)
IL (1) IL181969A0 (no)
MX (1) MX2007003116A (no)
NO (1) NO20071873L (no)
RU (1) RU2408596C2 (no)
TW (1) TW200616986A (no)
UA (1) UA88329C2 (no)
WO (1) WO2006032869A1 (no)
ZA (1) ZA200703079B (no)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0119865D0 (en) * 2001-08-14 2001-10-10 Cancer Res Campaign Tech DNA-PK inhibitors
SI1551372T1 (en) 2002-09-20 2018-08-31 Alpharma Pharmaceuticals Llc SUBVENCATION DATA AND RELATED CONSTRUCTIONS AND PROCEDURES
MXPA06001599A (es) * 2003-08-13 2006-05-19 Kudos Pharm Ltd Aminopironas y su uso como inhibidores de atm.
US20070238731A1 (en) 2004-09-20 2007-10-11 Kudos Pharmaceuticals Limited Dna-Pk Inhibitors
CN101115747A (zh) * 2005-02-09 2008-01-30 库多斯药物有限公司 Atm抑制剂
AR053358A1 (es) * 2005-04-15 2007-05-02 Cancer Rec Tech Ltd Inhibidores de adn - pk
EP1895997A2 (en) * 2005-05-26 2008-03-12 Kudos Pharmaceuticals Ltd Use of dna-pk inhibition to sensitise atm deficient cancers to dna-damaging cancer therapies
US20070049588A1 (en) * 2005-08-31 2007-03-01 Kudos Pharmaceuticals Limited Atm inhibitor
DK2526932T3 (en) 2006-06-19 2017-07-17 Alpharma Pharmaceuticals Llc Pharmaceutical composition
EP2073797A2 (en) * 2006-10-11 2009-07-01 Alpharma, Inc. Pharmaceutical compositions
UY31232A1 (es) * 2007-07-19 2009-03-02 Compuestos derivados de dibenzotifenilamino-cromen-4-onas activas sustituidas y sus isomeros y aplicaciones
US8623418B2 (en) 2007-12-17 2014-01-07 Alpharma Pharmaceuticals Llc Pharmaceutical composition
EP2224805A4 (en) * 2007-12-17 2013-10-16 Alpharma Pharmaceuticals Llc PHARMACEUTICAL COMPOSITION
US20110130386A1 (en) * 2008-04-25 2011-06-02 Mark Frigerio Dna-pk inhibitors
US20230022146A1 (en) 2019-06-17 2023-01-26 Vertex Pharmaceuticals Incorporated Compositions and methods for editing beta-globin for treatment of hemaglobinopathies
CA3205138A1 (en) 2020-12-17 2022-06-23 Vertex Pharmaceuticals Incorporated Compositions and methods for editing beta-globin for treatment of hemaglobinopathies

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1303724A (no) 1969-05-14 1973-01-17
JPH0753725B2 (ja) * 1987-10-08 1995-06-07 富山化学工業株式会社 4h―1―ベンゾピラン―4―オン誘導体およびその塩、それらの製造法並びにそれらを含有する抗炎症剤
US5284856A (en) * 1988-10-28 1994-02-08 Hoechst Aktiengesellschaft Oncogene-encoded kinases inhibition using 4-H-1-benzopyran-4-one derivatives
US5703075A (en) * 1988-12-21 1997-12-30 Pharmacia & Upjohn Company Antiatherosclerotic and antithrombotic 1-benzopyran-4-ones and 2-amino-1,3-benzoxazine-4-ones
HUT58310A (en) 1988-12-21 1992-02-28 Upjohn Co Anti-atherosclerotic and anti-thrombotic 1-benzopyran-4-one- and 2-amino-1,3-benzoxazin-4-one derivatives, process for producing them and pharmaceutical compositions containing them
JPH03215423A (ja) 1990-01-18 1991-09-20 Kyowa Hakko Kogyo Co Ltd 血管拡張剤
EP0525123B1 (en) 1990-06-20 1997-09-17 PHARMACIA & UPJOHN COMPANY Antiatherosclerotic and antithrombotic 1-benzopyran-4-ones and 2-amino-1,3-benzoxazine-4-ones
US5302613A (en) * 1990-06-29 1994-04-12 The Upjohn Company Antiatheroscleroic and antithrombotic 2-amino-6-phenyl-4H-pyran-4-ones
US5252735A (en) * 1990-06-29 1993-10-12 The Upjohn Company Antiatherosclerotic and antithrombotic 2-amino-6-phenyl-4H-pyran-4-ones
WO1992000290A1 (en) 1990-06-29 1992-01-09 The Upjohn Company Antiatherosclerotic and antithrombotic 2-amino-6-phenyl-4h-pyran-4-ones
EP0610519B1 (en) 1992-09-02 1999-12-01 Kyowa Hakko Kogyo Co., Ltd. Anti-hiv drug
AU698990B2 (en) * 1993-04-09 1998-11-19 Toyama Chemical Co. Ltd. Immunomodulator, cell adhesion inhibitor, and agent for treating and preventing autoimmune diseases
US5378725A (en) 1993-07-19 1995-01-03 The Arizona Board Of Regents Inhibition of phosphatidylinositol 3-kinase with wortmannin and analogs thereof
US5504103A (en) 1993-08-25 1996-04-02 Eli Lilly And Company Inhibition of phosphatidylinositol 3-kinase with 17 β-hydroxywortmannin and analogs thereof
US5441947A (en) 1993-08-25 1995-08-15 Eli Lilly And Company Methods of inhibiting vascular restenosis
US5468773A (en) 1993-08-25 1995-11-21 Eli Lilly And Company Methods for inhibiting bone loss and cartilage degradation using wortmannin and its analogs
CA2133815A1 (en) 1993-10-12 1995-04-13 Jeffrey Alan Dodge Inhibition of phosphatidylinositol 3-kinase with viridin, demethoxyviridin, viridiol, demethoxyviridiol, virone, wortmannolone, and analogs thereof
US6632789B1 (en) 1994-04-29 2003-10-14 The United States Of America As Represented By The Secretary Of The Navy Methods for modulating T cell responses by manipulating intracellular signal transduction
US5480906A (en) 1994-07-01 1996-01-02 Eli Lilly And Company Stereochemical Wortmannin derivatives
GB9521987D0 (en) 1995-10-26 1996-01-03 Ludwig Inst Cancer Res Phosphoinositide 3-kinase modulators
US5733920A (en) * 1995-10-31 1998-03-31 Mitotix, Inc. Inhibitors of cyclin dependent kinases
AU1461197A (en) 1995-11-16 1997-06-05 Icos Corporation Cell cycle checkpoint pik-related kinase materials and methods
GB2302021A (en) 1996-10-16 1997-01-08 Lilly Co Eli Inhibiting bone loss or resorption
WO1998055602A1 (en) 1997-06-06 1998-12-10 Mayo Foundation For Medical Education And Research Screening for phosphatidylinositol related-kinase inhibitors
AU8068198A (en) 1997-06-13 1998-12-30 President And Fellows Of Harvard College Methods for treating human cancers
FR2776291B1 (fr) 1998-03-18 2000-06-16 Pf Medicament Nouveaux derives bis-benzamides, leur procede de fabrication, les compositions pharmaceutiques les contenant et leur utilisation comme medicament
US6387640B1 (en) * 1999-02-10 2002-05-14 St. Jude Children's Research Hospital ATM kinase modulation for screening and therapies
US6348311B1 (en) * 1999-02-10 2002-02-19 St. Jude Childre's Research Hospital ATM kinase modulation for screening and therapies
US6333180B1 (en) * 1999-12-21 2001-12-25 International Flavors & Fragrances Inc. Bioprocess for the high-yield production of food flavor-acceptable jasmonic acid and methyl jasmonate
NZ520300A (en) 2000-01-24 2004-05-28 Kinacia Pty Ltd Morpholino-substituted pyridopyrimidine, quinolone and benzopyranone derivatives that inhibit the enzyme phosphoinositide (PI) 3-kinase
US6699997B2 (en) * 2000-06-28 2004-03-02 Teva Pharmaceutical Industries Ltd. Carvedilol
AU2001288432A1 (en) 2000-09-01 2002-03-22 Icos Corporation Materials and methods to potentiate cancer treatment
EP1353693B1 (en) 2001-01-16 2005-03-16 Glaxo Group Limited Pharmaceutical combination containing a 4-quinazolineamine and paclitaxel, carboplatin or vinorelbine for the treatment of cancer
GB0119865D0 (en) 2001-08-14 2001-10-10 Cancer Res Campaign Tech DNA-PK inhibitors
GB0119863D0 (en) * 2001-08-14 2001-10-10 Cancer Res Campaign Tech DNA-PK inhibitors
AU2002349912A1 (en) 2001-10-24 2003-05-06 Iconix Pharmaceuticals, Inc. Modulators of phosphoinositide 3-kinase
AU2002357667A1 (en) 2001-10-24 2003-05-06 Iconix Pharmaceuticals, Inc. Modulators of phosphoinositide 3-kinase
US7049313B2 (en) * 2002-02-25 2006-05-23 Kudos Pharmaceuticals Ltd. ATM inhibitors
BR0307944A (pt) 2002-02-25 2005-02-01 Kudos Pharm Ltd Piranonas úteis como inibidores de atm
ATE491703T1 (de) 2002-04-30 2011-01-15 Kudos Pharm Ltd Phthalazinonderivate
MXPA06001599A (es) * 2003-08-13 2006-05-19 Kudos Pharm Ltd Aminopironas y su uso como inhibidores de atm.
US20070238731A1 (en) 2004-09-20 2007-10-11 Kudos Pharmaceuticals Limited Dna-Pk Inhibitors
CN101115747A (zh) * 2005-02-09 2008-01-30 库多斯药物有限公司 Atm抑制剂
AR053358A1 (es) * 2005-04-15 2007-05-02 Cancer Rec Tech Ltd Inhibidores de adn - pk
UY31232A1 (es) * 2007-07-19 2009-03-02 Compuestos derivados de dibenzotifenilamino-cromen-4-onas activas sustituidas y sus isomeros y aplicaciones

Also Published As

Publication number Publication date
CN101061111A (zh) 2007-10-24
MX2007003116A (es) 2007-07-16
TW200616986A (en) 2006-06-01
JP2008513428A (ja) 2008-05-01
US20060106025A1 (en) 2006-05-18
UA88329C2 (en) 2009-10-12
BRPI0515498A (pt) 2008-07-29
CA2580229A1 (en) 2006-03-30
IL181969A0 (en) 2007-07-04
US20070238731A1 (en) 2007-10-11
US7732483B2 (en) 2010-06-08
US20080242664A1 (en) 2008-10-02
WO2006032869A1 (en) 2006-03-30
ZA200703079B (en) 2008-08-27
US7402607B2 (en) 2008-07-22
RU2007110629A (ru) 2008-10-27
AU2005286329A1 (en) 2006-03-30
RU2408596C2 (ru) 2011-01-10
KR20070059156A (ko) 2007-06-11
EP1794151A1 (en) 2007-06-13

Similar Documents

Publication Publication Date Title
NO20071873L (no) DNA-PK inhibotorer.
ECSP12012212A (es) Derivados de ariletinilo
CY1113687T1 (el) Παραγωγα αμινο νικοτινικου και ισο-νικοτινικου οξεος σαν παραγοντες καταστολης της dhodh
NO20083408L (no) Korrosjonsinhibitorer som har okt biologisk nedbrytbarhet og redusert giftighet
DK1417196T3 (da) DNA-PK inhibitorer
TW200605883A (en) Condensed heterocycle derivative having HCV inhibitory activity
CO6341609A2 (es) 5-heterociclilalquil-3-hidroxi-2-fenilciclopent-2-enonas como herbicidas.
ZA200601595B (en) Aminopyrones and their use as ATM inhibitors
CO6261379A2 (es) Compuestos de ciclopentandiona y derivados utiles como herbicidas
NO20076010L (no) Heterosyklisk forbindelse
CR8264A (es) Derivados de malonamida bloqueadores de la actividad gamma-secretase
NO20074071L (no) Hydrazinometyl, hydrozonometyl og 5-leddete heterocykliske forbindelser som virker som MTOR inhibitorer og anvendelse derav som anti-cancer midler
AR067613A1 (es) Inhibidores de adn-pk, uso y sintesis de los mismos
TNSN07255A1 (en) Cyclohexylamides as dopamine d3, d2 and 5ht 1a antagonists
TW200638938A (en) ATM inhibitors
MX2010001566A (es) Derivado de aminopirazolamida.
MX2010010471A (es) Derivado de tetrahidroisoquinolina novedoso.
GB2470170A (en) Dithienothiophene derivatives
DK2000473T3 (da) Trehalose-forbindelse og lægemiddel omfattende forbindelsen
ATE528284T1 (de) Metallcarbamate aus tolylendiaminen
MX2007007256A (es) Cetonas de piridina con efecto herbicida.
DK1899331T3 (da) Homomorpholinoxazolidnoner som antibakterielle midler
WO2009130469A8 (en) Dna-pk inhibitors
ATE525386T1 (de) 3'-ethynylcytidinderivat
MX2010008740A (es) Derivado de 3,8-diaminotetrahidroquinolina.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application